Gilead Sciences, Inc.
GILD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882095
In the last 90 days, Gilead Sciences, Inc. insiders filed 0 open-market purchases and 11 sales; 2,292 institutions reported holding it in 13F filings for Q2 2026, worth $140.5B in total; no superinvestor holds it.
Holders of 5% or more of GILD
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Gilead Sciences, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.20%101.7M shares | – | Apr 24, 20251 filing | Apr 24, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 7.51%93.3M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| FMR LLC | 13G | 5.30%65.5M shares | New | Feb 5, 20261 filing | Feb 5, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
19 Schedule 13D and 13G filings on Gilead Sciences, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Apr 29, 20266:41 PM ET | Vanguard Capital Management LLC | 13G | 7.51%93.3M shares | New | Mar 31, 2026 | SEC |
| Mar 26, 20266:40 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 5, 20261:23 PM ET | FMR LLCand 1 other | 13G | 5.30%65.5M shares | New | Dec 31, 2025 | SEC |
| May 13, 202511:44 AM ET | Capital World Investors | 13G/A | 4.30%53.8M shares | –Below 5% | Mar 31, 2025 | SEC |
| Apr 24, 20259:27 AM ET | BlackRock, Inc. | 13G/A | 8.20%101.7M shares | – | Mar 31, 2025 | SEC |
| Feb 13, 2024 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | Capital World Investors | 13G/AOld format | – | – | – | SEC |
| Jan 24, 20242:27 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2023 | Capital World Investors | 13GOld format | – | New | – | SEC |
| Feb 13, 2023 | Capital Research Global Investors | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Jan 31, 20238:55 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jul 8, 20224:56 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Feb 11, 2022 | Capital Research Global Investors | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 1, 20225:14 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Capital Research Global Investors | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Capital Research Global Investors | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2021 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20219:56 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Gilead Sciences, Inc. shares.
No Form 144 notices for Gilead Sciences, Inc. are on file.